- Zacks•20 hours ago
Merck & Co., Inc. (MRK) recently announced that its anti-PD-1 therapy, Keytruda, has received positive opinion from CHMP for the treatment of patients with relapsed or refractory classical hodgkin lymphoma (cHL).
- TheStreet.com•4 days ago
The vote on repealing and replacing Obamacare has been pulled from the House floor.
- Market Realist•4 days ago
On a capital-structure-neutral basis, Merck currently trades at ~9.6x, which is much lower than the industry average of ~11.2x.
MRK.BA : Summary for MERCK & CO INC CEDEAR (10 REP 1 - Yahoo Finance
Merck & Co., Inc. (MRK.BA)
Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
Add to watchlist
|Day's Range||105.00 - 105.00|
|52 Week Range||97.55 - 105.00|
|PE Ratio (TTM)||74.47|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|